Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
16.31
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
16.35
+0.04 (0.25%)
After-hours: Mar 27, 2026, 5:31 PM EDT
Pharming Group Employees
Pharming Group had 404 employees as of December 31, 2024. The number of employees increased by 22 or 5.76% compared to the previous year.
Employees
404
Change (1Y)
22
Growth (1Y)
5.76%
Revenue / Employee
$931,025
Profits / Employee
$7,057
Market Cap
1.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 404 | 22 | 5.76% |
| Dec 31, 2023 | 382 | 50 | 15.06% |
| Dec 31, 2022 | 332 | 55 | 19.86% |
| Dec 31, 2021 | 277 | 15 | 5.73% |
| Dec 31, 2020 | 262 | 50 | 23.58% |
| Jan 1, 2020 | 212 | 29 | 15.85% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vir Biotechnology | 367 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| Olema Pharmaceuticals | 131 |
| Septerna | 130 |
| DBV Technologies | 117 |
| ORIC Pharmaceuticals | 104 |
| Taysha Gene Therapies | 99 |
PHAR News
- 1 day ago - Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older - GlobeNewsWire
- 4 days ago - Pharming Group's Leniolisib Gets Japan Approval To Treat APDS Patients Aged 4 Years And Older - Nasdaq
- 4 days ago - Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older - GlobeNewsWire
- 15 days ago - Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 15 days ago - Q4 2025 Pharming Group NV Earnings Call Transcript - GuruFocus
- 15 days ago - Earnings Scheduled For March 12, 2026 - Benzinga
- 16 days ago - Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow - GlobeNewsWire
- 16 days ago - Pharming Group (XAMS:PHARM) Q4 2025 Earnings Report Preview: What to Expect - GuruFocus